Adam Elhofy, PhD

VP of Research and Innovation
COUR Pharma

Poster(s):

• Th102 - CNP-104, an Antigen-Specific Tolerogenic Nanoparticle Therapy, Stabilizes Prognostic Trajectory and Liver Stiffness with a Link to Reduction in Pathogenic T-Cells in Primary Biliary Cholangitis
  Thursday, June 11, 2026

  7:00 PM - 8:15 PM PST